The ThinPrep Difference

FDA-Approved and Chosen by Physicians

The ThinPrep Pap Test is the most comprehensive, FDA-approved, liquid-based pap test available. It offers increased HSIL detection,1 and is the only liquid-based pap test FDA-approved for HPV, Chlamydia, and Gonorrhea testing directly from the same vial. Additionally, it is the only pap test for which the FDA has approved labeling supported by multiple peer-reviewed publications2-7 reporting improved glandular disease detection.

The significance of FDA approvals

To obtain FDA approval, manufacturers must meet rigorous testing criteria demonstrating that their product is safe and effective.8 The criteria require valid scientific evidence to ensure consistent and reproducible product performance, such that the particular requirements for the specific intended use can be fulfilled consistently. The ThinPrep Pap Test met these criteria so that physicians, lab personnel, and patients can be confident using the ThinPrep Pap Test specimen for such tests. In fact, governing bodies such as the American Society for Colposcopy and Cervical Pathology noted that:

"The appropriate use of [ASCCP] guidelines require that laboratories utilize only HPV tests that have been analytically and clinically validated with proven, acceptable reproducibility, clinical sensitivity, specificity, and positive and negative predictive values for cervical cancer and verified precancer (CIN 2,3) as documented by the Food and Drug Administration (FDA) approval and/or publication in peer-reviewed scientific literature."

— American Journal of Obstetrics and Gynecology, October 2007

FDA-approved out of the vial tests

The ThinPrep Pap Test is the only pap test to secure FDA approvals for ancillary testing including:

  • HPV DNA testing with Cervista™ HPV HR
  • HPV DNA genotyping with Cervista™ HPV 16/18
  • HPV DNA testing with the Digene Hybrid Capture® 2 (Digene® HPV Test)*
  • Chlamydia and Gonorrhea testing with the Roche COBAS AMPLICOR™*
  • Chlamydia and Gonorrhea testing with the Gen-Probe APTIMA COMBO 2® *

The ThinPrep Pap Test is also the only pap test supported by multiple peer reviewed studies2-7 to meet the FDA standards for improved glandular disease detection.

*Hybrid Capture® 2 (hc2) and Digene® HPV Test are registered trademarks of QIAGEN Group. COBAS AMPLICOR™ is a trademark of Roche Diagnostics Corporation. APTIMA COMBO 2® is a registered trademark of Gen-Probe Inc.

References

1. Versus the Conventional Pap Smear, Hologic, Inc. The ThinPrep Pap Test package insert results based on a multi-site prospective, historically-controlled, direct-to-vial study of routine screening and referral patient populations at 10 leading academic institutions resulting in a 59.7% increase in detection of HSIL+ lesions for ThinPrep specimens.

2. Bai H, Sung CJ, Steinhoff MM. ThinPrep Pap Test promotes detection of glandular lesions of the endocervix. Diagn Cytopathol. 2000;23:19-22.

3. Carpenter AB, Davey DD. ThinPrep Pap Test: performance biopsy follow-up in a university hospital. Cancer. 1999;87:105-12.

4. Guidos BJ, Selvaggi SM. Detection of endometrial adenocarcinoma with the ThinPrep Pap Test. Diagn Cytopathol. 2000;23:260-5.

5. Schorge JO, Hossein Saborian M, Hynan L, et al. ThinPrep detection of endometrial adenocarcinoma: a retrospective cohort study. Cancer Cytopathol. 2002;96:338-43.

6. Wang N, Emancipator SN, Rose P, et al. Histologic follow-up of atypical endocervical cells. Liquid-based, thin-layer preparation vs. conventional pap smear. Acta Cytol. 2002;46:453-7.

7. Ashfaq R, Gibbons D, Vela C, Saboorian MH, Iliya F. ThinPrep Pap Test accuracy for glandular disease. Acta Cytol. 1999;43:81-5.

8. U.S. Food and Drug Administration. FDA Heart Health Online. Available at: http://www.fda.gov/hearthealth/faqs/faqs.html. Accessed 4/30/08.

See why 60% of all ThinPrep Pap Tests are now imaged.

Find out more

See a list of key studies involving the ThinPrep
Pap Test and the ThinPrep Imaging System.

Get bibliography

Privacy | Terms | Sitemap